Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 4

Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

,

Panelists discuss how treatment goals for patients with lower-risk MDS are established and analyze the findings of Oliva et al’s study on the relationship between hemoglobin levels and quality of life in transfusion-dependent patients with lower-risk MDS treated with luspatercept or epoetin.

Video content above is prompted by the following:

  • What are your treatment goals for patients with lower-risk MDS?
  • Please comment on the findings of Oliva et al with regard to the relationship between hemoglobin levels and quality of life in transfusion-dependent patients with lower-risk MDS treated with luspatercept or epoetin (EHA 2024; abstract P774).